Oral peptide antagonists targeting the IL-23/IL-17 axis represent an innovative and promising therapeutic class for chronic immune-mediated diseases. Icotrokinra (JNJ-2113), a first-in-class oral IL-23 receptor antagonist peptide, has demonstrated robust clinical efficacy and a favorable safety profile across multiple inflammatory conditions. In Phase 3 psoriasis trials, it achieved high rates of skin clearance, including in areas that are typically difficult to treat. Beyond dermatology, Icotrokinra has shown potential in Phase 2 trials for ulcerative colitis and is advancing into Phase 3 development for both ulcerative colitis and Crohn’s disease.
Complementing this is PN-881, a next-generation oral IL-17 antagonist peptide with potent and selective inhibition across three IL-17 dimers (AA, AF, and FF), with excellent stability, and compelling efficacy in preclinical inflammation models.
Together, these programs highlight the transformative potential of oral peptides in redefining treatment approaches for inflammatory diseases. In this presentation, I will share key clinical findings from Icotrokinra and preclinical insights into the PN-881 program.